Atai & Beckley Psychedelic Merger Creates Global Mental Health Leader
Atai Life Sciences and Beckley Psytech are merging in an all-stock transaction, creating atai Beckley, a leading mental health...
Search results for:
AI
Taiho Pharma Zipalertinib Shows Promise in Pivotal Phase 2b Trial
Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology announced positive Phase 2b results from the REZILIENT1 trial of zipalertinib, an...
Risvodetinib for Parkinson’s: End of Phase 2 FDA Meeting Details Announced
ABLi Therapeutics recently completed an End of Phase 2 meeting with the FDA to discuss results from their Parkinson’s...
Scaling GenAI in Life Sciences: Overcoming Barriers with Strategy, Compliance, and Human Insight
As GenAI gains traction across life sciences, the conversation is rapidly shifting from potential to practicality. Yet, many organizations...
Transforming Clinical Trials: Anca Copaescu on Clinical Trial Business Infrastructure, AI, and Vendor Management
In this interview, Anca Copaescu, Founder and CEO at Strategikon, explores the complexities of clinical trial management. Anca provides...
4-Year Data Shows Sustained Response to Transcon PTH Therapy
Ascendis Pharma A/S released 214-week data from its Phase 2 PaTH Forward Trial of TransCon PTH (palopegteriparatide) for adults...
PDS Biotech Reveals Details on Universal Flu Studies at Immunology2025™
PDS Biotechnology Corporation announced preclinical data on its investigational Infectimune®-based flu vaccine at the IMMUNOLOGY2025™ Annual Meeting. Studies conducted...
Alzamend Neuro and Qmenta in AI Imaging Trial
Alzamend Neuro is partnering with QMENTA to utilize their AI-driven imaging platform in five upcoming Phase II clinical trials...
Macro Trends in Pharma: AI, Innovation, and the Impact on Outsourcing Strategy
At SCOPE Summit 2025, a panel discussion explored the industry’s macro trends, focusing on AI, innovation, and outsourcing strategies....
Annexon at AAN: GBS Data & New Education Campaign
Annexon, Inc. presented Phase 3 trial data for tanruprubart (formerly ANX005), a C1q-blocking monoclonal antibody, at the 2025 AAN...